Biocryst Pharmaceuticals (BCRX) Shares Outstanding (Weighted Average) (2010 - 2026)

Biocryst Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $242.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 15.98% year-over-year to $242.3 million; the trailing twelve-month figure through Mar 2026 stood at $242.3 million (up 15.98% YoY), and the FY2025 full-year result was $209.9 million, up 1.55% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $242.3 million, up from $209.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $242.3 million in Q1 2026, with the low at $184.9 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $200.5 million across 5 years, with a median of $206.1 million in 2024.
• Annual changes were most pronounced in 2025 — Shares Outstanding (Weighted Average) climbed 1.37% — and 2026, when it grew 15.98%.
• Biocryst Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $185.9 million in 2022, then advanced by 3.38% to $192.2 million in 2023, then gained by 7.54% to $206.7 million in 2024, then increased by 1.55% to $209.9 million in 2025, then advanced by 15.42% to $242.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $242.3 million (Q1 2026), $209.9 million (Q4 2025), and $210.2 million (Q3 2025), per Business Quant data.